Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal
BERLIN (Reuters) -Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 billion merger deal with a special-purpose acquisition vehicle, or SPAC. The planned merger with the SPAC Voyager Acquisition values Veraxa, cancer drug developer, at about $1.3 billion excluding trust …
Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC deal Read More »










